Use of human placental perfusate cells in the manufacture of a medicament for suppressing the proliferation of blood cancer cells, wherein the placental perfusate cells are (a) total nucleated cells from placental perfusate, (b) placental perfusate cells that have been treated to remove at least one type of cell, or (c) placental perfusate cells that have been treated to enrich for at least one type of cell； and wherein said placental perfusate cells are contacted with an immunomodulatory compound in an amount and for a time sufficient for said perfusate cells to exhibit detectably more cytotoxicity towards said blood cancer cells than an equivalent number of perfusate cells not contacted with said immunomodulatory compound.Humane ćelije sa jedrom perfuzata placente za korišćenje u postupku lečenja tumora kod osobe, pri čemu humane ćelije sa jedrom perfuzata placente obuhvataju CD56+, CD 16- placentne intermedijerne ćelije prirodne ubice i one koje se mogu dobiti perfuzijom humane placente koja je bila drenirana od pupčane krvi i isprana radi uklanjanja zaostale krvi da bi se proizveo perfuzat placente koji sadrži placentne ćelije sa jedrom； i izolacija placenthih ćelija sa jedrom iz navedenog perfuzata placente.Prijava sadrži još 14 patentnih zahteva.
